Pharmacogenetic testing by polymorphic markers G1846A (CYP2D6∗4) and C100T (CYP2D6∗10) of the CYP2D6 gene in coronary heart disease patients taking...
Fedorinov D. S., Mirzaev K. B., Mustafina V. R., Sy'chev D. A., Maximova N. R., Chertovskikh J. V., Popova N. V., Tarabukina S. M., Rudykh Z. A.
Drug Metabolism and Personalized Therapy
Vol.33, Issue4, P. 195-200
Опубликовано: 2018
Тип ресурса: Статья
DOI:10.1515/dmpt-2018-0015
Аннотация:
The aim of this study was to determine carrier frequencies of the polymorphic markers G1846A (CYP2D6∗4) and C100T (CYP2D6∗10) of the CYP2D6 gene in coronary heart disease (CHD) patients in Russian and Yakut ethnic groups. The association between the administration of higher doses of bisoprolol and metoprolol and the carriage of these polymorphic markers related to the decreased function of the haplotype of CYP2D6 was also studied. The study included 201 CHD patients (aged 66±8.7 years) receiving metoprolol in titrated dose (12.5-150 mg), bisoprolol (2.5-10 mg) or atenolol (50 mg). Ninety-three patients were Russian (30 men and 63 women), and 108 patients were Yakut (54 men and 54 women). In genotyping CHD patients in the Russian and Yakut ethnic groups, there was no significant difference in the prevalence rate of the polymorphic markers G1846A (10.8 vs. 10.2; p=0.871) and C100T (16.1 vs. 16.2; p=1). In patients carrying the polymorphic marker G1846A, the dose of bisoprolol was establi
Ключевые слова:
bisoprolol; CYP2D6; CYP2D6; metoprolol; pharmacogenetics; Russians; Yakuts
atenolol; beta adrenergic receptor blocking agent; bisoprolol; cytochrome P450 2D6; genomic DNA; metoprolol; beta adrenergic receptor blocking agent; cytochrome P450 2D6; aged; allele; Article; controlled study; CYP2D6 gene; DNA isolation; DNA polymorphism; drug dose titration; drug megadose; female; gene; gene frequency; gene mutation; genetic marker; genotype; haplotype; human; ischemic heart disease; major clinical study; male; pharmacogenetics; polymerase chain reaction; prevalence; real time polymerase chain reaction; Yakutia; blood; coronary artery disease; dose response; genetics; middle aged; pharmacogenetic testing; Russian Federation; single nucleotide polymorphism; Adrenergic beta-Antagonists; Aged; Coronary Disease; Cytochrome P-450 CYP2D6; Dose-Response Relationship, Drug; Gene Frequency; Humans; Male; Middle Aged; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Russia
Язык текста: Английский
ISSN: 2363-8915
Fedorinov D. S. Denis Sergeevich 1996-
Mirzaev K. B. Karin Badavievich 1991-
Mustafina V. R. Violetta Rafae`levna 1995-
Sy'chev D. A. Dmitrij Alekseevich 1975-
Maximova N. R.
Chertovskikh J. V.
Popova N. V.
Tarabukina S. M.
Rudykh Z. A.
Федоринов Д. С. Денис Сергеевич 1996-
Мирзаев К. Б. Карин Бадавиевич 1991-
Мустафина В. Р. Виолетта Рафаэлевна 1995-
Сычев Д. А. Дмитрий Алексеевич 1975-
Махимова Н. Р.
Чертовских Й. В.
Попова Н. В.
Тарабукина С. М.
Рудyх З. А.
Pharmacogenetic testing by polymorphic markers G1846A (CYP2D6∗4) and C100T (CYP2D6∗10) of the CYP2D6 gene in coronary heart disease patients taking ββ-blockers in the Republic of Sakha (YAKUTIA)
Pharmacogenetic testing by polymorphic markers G1846A (CYP2D6∗4) and C100T (CYP2D6∗10) of the CYP2D6 gene in coronary heart disease patients taking...
Текст визуальный непосредственный
Drug Metabolism and Personalized Therapy
Walter de Gruyter GmbH
Vol.33, Issue4 P. 195-200
2018
Статья
bisoprolol CYP2D6 CYP2D6 metoprolol pharmacogenetics Russians Yakuts
atenolol beta adrenergic receptor blocking agent bisoprolol cytochrome P450 2D6 genomic DNA metoprolol beta adrenergic receptor blocking agent cytochrome P450 2D6 aged allele Article controlled study CYP2D6 gene DNA isolation DNA polymorphism drug dose titration drug megadose female gene gene frequency gene mutation genetic marker genotype haplotype human ischemic heart disease major clinical study male pharmacogenetics polymerase chain reaction prevalence real time polymerase chain reaction Yakutia blood coronary artery disease dose response genetics middle aged pharmacogenetic testing Russian Federation single nucleotide polymorphism Adrenergic beta-Antagonists Aged Coronary Disease Cytochrome P-450 CYP2D6 Dose-Response Relationship, Drug Gene Frequency Humans Male Middle Aged Pharmacogenomic Testing Polymorphism, Single Nucleotide Russia
The aim of this study was to determine carrier frequencies of the polymorphic markers G1846A (CYP2D6∗4) and C100T (CYP2D6∗10) of the CYP2D6 gene in coronary heart disease (CHD) patients in Russian and Yakut ethnic groups. The association between the administration of higher doses of bisoprolol and metoprolol and the carriage of these polymorphic markers related to the decreased function of the haplotype of CYP2D6 was also studied. The study included 201 CHD patients (aged 66±8.7 years) receiving metoprolol in titrated dose (12.5-150 mg), bisoprolol (2.5-10 mg) or atenolol (50 mg). Ninety-three patients were Russian (30 men and 63 women), and 108 patients were Yakut (54 men and 54 women). In genotyping CHD patients in the Russian and Yakut ethnic groups, there was no significant difference in the prevalence rate of the polymorphic markers G1846A (10.8 vs. 10.2; p=0.871) and C100T (16.1 vs. 16.2; p=1). In patients carrying the polymorphic marker G1846A, the dose of bisoprolol was establi